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nvolvement, interval between appearance of lesions and diagnosis
nd number of cutaneous lesions in each affected person.
Results: Results showed that cutaneous leishmaniasis was
bserved more in children younger than 15 years-old.
Although, 44.9% of all patients were females and 51.1% were
ales but sex factor of the patients was not statistically signiﬁcant.
his investigation demonstrated that 44.4% had only one lesion.
ore than one skin lesion reported in 55.6% of the patients that is
ndicated that sand- ﬂy, for complete feeding, bites it’s host more
han one time or more than one sand ﬂy bite patients.
Conclusion: In order to prevention of leishmaniasis, health edu-
ation about this disease and also providing protection facilities are
ecommended in endemic areas.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.689
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Background: Malaria causes substantial illness and death in
he world’s population, especially in children less than 5 years
ld. Pyronaridine/Artesunate (PA) 3:1 ﬁxed dose combination is
novel artemisinin combination therapy (ACT) in development
or the treatment of acute uncomplicated Plasmodium falciparum
nd blood stage of P. vivax malaria. Tablet (180:60mg PA) and
ediatric granule (60:20mg PA) formulations are under parallel
evelopment for clinical use. The purpose of this study is to use
harmacokinetic modeling and simulation to explore exposure
mong pediatric dosing groups for 3 PA dosing regimens.
Methods: Population pharmacokinetics of pyronaridine was
onducted using non-linear mixed effect modeling. The pharma-
okinetic model incorporated data from healthy (166) and malaria
nfected (642) subjectsparticipating inninePhase I-III clinical trials.
ge ranged from 0.6 to 60 years and weight from 9 to 90.1 kg. Inﬂu-
nces of age, weight, bodymass index,malaria infection, creatinine
learance, alanine aminotransferase, aspartate aminotransferase,
ender, and ritonavir administration on pyronaridine pharmacoki-
etics were evaluated. Monte Carlo simulations were performed to
eﬂect pyronaridine exposure in pediatric malaria patients based
ncurrentdosing recommendations. Typical pyronaridineAUCval-
es expected for pediatric malaria patients of weights between
-20kg were obtained using covariate parameter relationship of
he ﬁnal model and the current dosage recommendations.
Results: Pyronaridine pharmacokinetics was best described by
two-compartment model with ﬁrst order absorption and elim-
nation from the central compartment. Signiﬁcant covariates on
yronaridinepharmacokinetics includedweight on apparent clear-
nce (CL/F), apparent central volume of distribution (V2/F), and
pparent peripheral volume of distribution (V3/F) and malaria
nfection on CL/F, and V2/F. Pyronaridine exposures for pediatricfectious Diseases 16S (2012) e158–e316 e159
malaria patients are shown for 3 PAweight-based dosing regimens.
Figure. Box-plot depicting number of sachets and Ln(AUC)
distribution of pyronaridine based on current dosing recom-
mendations for pediatric malaria patients; bars represent 25th
and 75th percentiles; whiskers represent 10th and 90th per-
centiles.
Conclusion: These results suggest that the use of PK model-
ing and simulation with adult and pediatric data can be used to
select appropriate dosing regimens in children. Simulations were
conducted using population pharmacokinetic modeling to show
weight-based dosing produces consistent pyronaridine exposure
among dosing groups in pediatric malaria patients between 5 and
20kg and drug exposures that are similar to those achieved in
adults.
http://dx.doi.org/10.1016/j.ijid.2012.05.690
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Clinical presentations of ALA (amoebic liver abscess) among
tuak consumers in Medan
F. Ginting
Faculty of Medicine University of Sumatera Utara/Adam Malik Central
Hospital, Medan, Indonesia
Background: Amoebiasis is endemic in many tropical countries
including Indoensia. Amoebic liver abscess (ALA) is one of the most
important extraintestinal amoebiasis, which alcoholism is one of
the risk factors. Tuak is a traditional beverage contains 15 – 25%
alcohol inMedan. The presentation of amoebic liver abscess among
tuak consumers in Medan has not been studied.
Objective: To describe the presentation of ALA among tuak con-
sumers in Medan.
Methods: This is an observational study conducted from May
2007 to March 2012 and included all of the patients with amoe-
bic liver abscess. The diagnosis of liver abscess was based on the
clinical appearances and USG. The presentations of ALA which
were recorded include fever, leucocytosis, and hepatomegaly. The
abscess puncture was performed for etiology conﬁrmation. All of
the patients received metronidazole and paramomycin. We per-
